Structure Therapeutics Highlights Aleniglipron Phase 2b Success
SAN FRANCISCO, June 5, 2026 Structure Therapeutics Inc. announced the publication of detailed results from its Phase 2b ACCESS...
Obesity
Advertisement
Zealand Pharma Highlights Positive Phase III Survodutide Results in Obesity
COPENHAGEN, Denmark, June 7, 2026 Zealand Pharma A/S announced that its partner Boehringer Ingelheim presented detailed results from the...
Eos SENOLYTIX Highlights PTC-2105 Preclinical Data at Obesity Forum
HOUSTON, Texas, June 5, 2026 Eos SENOLYTIX, Inc. presented new preclinical findings for its lead MitoXcel™ geropeptide candidate PTC-2105...
Genentech Advances Obesity Portfolio with New ADA 2026 Data
SOUTH SAN FRANCISCO, Calif., May 31, 2026 Genentech, a member of the Roche Group, announced that new clinical data...
Eli Lilly Retatrutide Phase 3 Trial Delivers Major Weight Loss
INDIANAPOLIS, May 21, 2026 Eli Lilly and Company announced positive topline results from its pivotal Phase 3 TRIUMPH-1 clinical...
Advertisements
MetaVia Highlights Vanoglipel’s MASH Fibrosis Potential
CAMBRIDGE, Mass., May 20, 2026 MetaVia Inc. has announced the publication of new peer-reviewed preclinical research supporting the anti-fibrotic...
Innovent Highlights Obesity Pipeline at ADA 2026
SAN FRANCISCO and SUZHOU, China, May 12, 2026 Innovent Biologics announced that it will present multiple clinical and preclinical...
Novo Nordisk Reports 28% Weight Loss With Higher-Dose Wegovy
Bagsværd, Denmark, May 12, 2026 Novo Nordisk presented new analyses from its pivotal STEP UP clinical trial at the...
Ascletis Advances ASC30 Phase II Trial in Diabetes
Hong Kong | April 27, 2026 Ascletis Pharma Inc. has announced the successful completion of enrollment in its U.S....
Lilly Foundayo Shows Strong Phase 3 Diabetes Results
INDIANAPOLIS, April 16, 2026 Eli Lilly and Company announced positive results from its ACHIEVE-4 Phase 3 clinical trial, demonstrating...
Advertisement
